238 related articles for article (PubMed ID: 32669010)
1. The role of soluble receptor for advanced glycation end-products (sRAGE) in the general population and patients with diabetes mellitus with a focus on renal function and overall outcome.
Steenbeke M; De Bruyne S; De Buyzere M; Lapauw B; Speeckaert R; Petrovic M; Delanghe JR; Speeckaert MM
Crit Rev Clin Lab Sci; 2021 Mar; 58(2):113-130. PubMed ID: 32669010
[TBL] [Abstract][Full Text] [Related]
2. Is there any evidence that AGE/sRAGE is a universal biomarker/risk marker for diseases?
Prasad K
Mol Cell Biochem; 2019 Jan; 451(1-2):139-144. PubMed ID: 29961210
[TBL] [Abstract][Full Text] [Related]
3. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes.
Tam XH; Shiu SW; Leng L; Bucala R; Betteridge DJ; Tan KC
Clin Sci (Lond); 2011 Jan; 120(2):81-9. PubMed ID: 20726839
[TBL] [Abstract][Full Text] [Related]
4. Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study.
Melin EO; Dereke J; Hillman M
Lipids Health Dis; 2020 Oct; 19(1):223. PubMed ID: 33054750
[TBL] [Abstract][Full Text] [Related]
5. Modulation of soluble receptor for advanced glycation end products isoforms and advanced glycation end products in long-living individuals.
Scavello F; Tedesco CC; Castiglione S; Maciag A; Sangalli E; Veglia F; Spinetti G; Puca AA; Raucci A
Biomark Med; 2021 Aug; 15(11):785-796. PubMed ID: 34236256
[TBL] [Abstract][Full Text] [Related]
6. Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE.
Moriya S; Yamazaki M; Murakami H; Maruyama K; Uchiyama S
J Stroke Cerebrovasc Dis; 2014; 23(10):2540-2546. PubMed ID: 25282185
[TBL] [Abstract][Full Text] [Related]
7. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker.
Yamagishi S; Matsui T
Front Biosci (Elite Ed); 2010 Jun; 2(4):1184-95. PubMed ID: 20515790
[TBL] [Abstract][Full Text] [Related]
8. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality.
Prasad K
Int J Angiol; 2014 Mar; 23(1):11-6. PubMed ID: 24627612
[TBL] [Abstract][Full Text] [Related]
9. Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study.
Sabbatinelli J; Castiglione S; Macrì F; Giuliani A; Ramini D; Vinci MC; Tortato E; Bonfigli AR; Olivieri F; Raucci A
Cardiovasc Diabetol; 2022 Jun; 21(1):95. PubMed ID: 35668468
[TBL] [Abstract][Full Text] [Related]
10. The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases.
Steenbeke M; Speeckaert R; Desmedt S; Glorieux G; Delanghe JR; Speeckaert MM
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408796
[TBL] [Abstract][Full Text] [Related]
11. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
12. Systemic levels of the anti-inflammatory decoy receptor soluble RAGE (receptor for advanced glycation end products) are decreased in dogs with inflammatory bowel disease.
Heilmann RM; Otoni CC; Jergens AE; Grützner N; Suchodolski JS; Steiner JM
Vet Immunol Immunopathol; 2014 Oct; 161(3-4):184-92. PubMed ID: 25183017
[TBL] [Abstract][Full Text] [Related]
13. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.
Isoyama N; Leurs P; Qureshi AR; Bruchfeld A; Anderstam B; Heimburger O; Bárány P; Stenvinkel P; Lindholm B
Nephrol Dial Transplant; 2015 Jan; 30(1):84-91. PubMed ID: 25074436
[TBL] [Abstract][Full Text] [Related]
14. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
[TBL] [Abstract][Full Text] [Related]
15. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target.
Geroldi D; Falcone C; Emanuele E
Curr Med Chem; 2006; 13(17):1971-8. PubMed ID: 16842191
[TBL] [Abstract][Full Text] [Related]
16. Emerging markers of inflammation and oxidative stress as potential predictors of coronary artery disease.
Tsirebolos G; Tsoporis JN; Drosatos IA; Izhar S; Gkavogiannakis N; Sakadakis E; Triantafyllis AS; Parker TG; Rallidis LS; Rizos I
Int J Cardiol; 2023 Apr; 376():127-133. PubMed ID: 36758863
[TBL] [Abstract][Full Text] [Related]
17. Sympathoadrenergic suppression improves heart function by upregulating the ratio of sRAGE/RAGE in hypertension with metabolic syndrome.
Selejan SR; Linz D; Tatu AM; Hohl M; Speer T; Ewen S; Mahfoud F; Kindermann I; Zamyatkin O; Kazakov A; Laufs U; Böhm M
J Mol Cell Cardiol; 2018 Sep; 122():34-46. PubMed ID: 30096408
[TBL] [Abstract][Full Text] [Related]
18. AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease.
Prasad K; Dhar I; Zhou Q; Elmoselhi H; Shoker M; Shoker A
Mol Cell Biochem; 2016 Dec; 423(1-2):105-114. PubMed ID: 27714575
[TBL] [Abstract][Full Text] [Related]
19. High Plasma sRAGE (Soluble Receptor for Advanced Glycation End Products) Is Associated With Slower Carotid Intima-Media Thickness Progression and Lower Risk for First-Time Coronary Events and Mortality.
Grauen Larsen H; Marinkovic G; Nilsson PM; Nilsson J; Engström G; Melander O; Orho-Melander M; Schiopu A
Arterioscler Thromb Vasc Biol; 2019 May; 39(5):925-933. PubMed ID: 30917679
[TBL] [Abstract][Full Text] [Related]
20. Soluble receptor for advanced glycation end products protects from ischemia- and reperfusion-induced acute kidney injury.
Miyagawa T; Iwata Y; Oshima M; Ogura H; Sato K; Nakagawa S; Yamamura Y; Kamikawa Y; Miyake T; Kitajima S; Toyama T; Hara A; Sakai N; Shimizu M; Furuichi K; Munesue S; Yamamoto Y; Kaneko S; Wada T
Biol Open; 2022 Jan; 11(1):. PubMed ID: 34812852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
